AROTINOLOL HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C15H21N3O2S3.ClH
Molecular Weight	408.002
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC(C)(C)NCC(O)CSC1=NC(=CS1)C2=CC=C(S2)C(N)=O

InChI

InChIKey=XXDAXBZYUXLDRD-UHFFFAOYSA-N

InChI=1S/C15H21N3O2S3.ClH/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20;/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20);1H

HIDE SMILES / InChI

Molecular Formula	C15H21N3O2S3
Molecular Weight	371.541
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11675958
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/6200619

Arotinolol (INN, marketed under the tradename Almarl) is a medication in the class of mixed alpha/beta blockers. It is used in the treatment of high blood pressure and essential tremor. The recommended dosage is 10–30 mg per day.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 87 Target ID: CHEMBL2094118 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6200619	Antagonist 2778
Adrenergic receptor alpha 64 Target ID: CHEMBL2095203 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6200619	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11675958	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Synthesis and beta-adrenergic blocking action of a new thiazolylthiopropanolamine derivative.	1978 Sep	29117
Effects of beta-adrenergic blockers with different ancillary properties on lipid peroxidation in hyperthyroid rat cardiac muscle.	1989 Oct	2575990
Enantioselective determination of arotinolol in human plasma by HPLC using teicoplanin chiral stationary phase.	2003 Oct	14598329
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443

Patents

Sample Use Guides

In Vivo Use Guide

10-20 mg twice daily for 4 weeks

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:02:56 GMT 2023` Edited by `admin` on `Fri Dec 15 17:02:56 GMT 2023`
Record UNII	9DOI1HT306
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AROTINOLOL HYDROCHLORIDE

Common Name

English

AROTINOLOL HYDROCHLORIDE [MART.]

Common Name

English

Arotinolol hydrochloride [WHO-DD]

Common Name

English

AROTINOLOL HCL

Common Name

English

AROTINOLOL HYDROCHLORIDE [JAN]

Common Name

English

2-THIOPHENECARBOXAMIDE, 5-(2-((3-((1,1-DIMETHYLETHYL)AMINO)-2-HYDROXYPROPYL)THIO)-4-THIAZOLYL)-, MONOHYDROCHLORIDE, (±)-

Common Name

English

(±)-2-(3'-TERT-BUTYLAMINO-2'-HYDROXYPROPYLTHIO)-4-(5'-CARBAMOYL-2'-THIENYL)THIAZOLE HCL

Common Name

English

AROTINOLOL HYDROCHLORIDE [MI]

Common Name

English

Code System Code Type Description

MERCK INDEX

m2052